Skip to main content

Fomivirsen ophthalmic Side Effects

Medically reviewed by Drugs.com. Last updated on Jul 8, 2022.

Applies to fomivirsen ophthalmic: intraocular solution.

Ocular

Most adverse effects associated with fomivirsen therapy are limited to the treated eye. However, some of these events (e.g. retinal detachment) will also occur with the natural progression of CMV retinitis and may not necessarily be direct complications of drug administration.

The most frequently observed adverse effect is ocular inflammation, including iritis and vitritis. Inflammatory reactions occur in approximately 25% of patients and are more common during induction dosing. Other frequently reported ocular effects (occurring in 5% to 25% of patients) include abnormal vision, anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, decreased visual acuity, desaturation of color vision, eye pain, floaters, increased intraocular pressure, photophobia, retinal detachment, retinal edema, retinal hemorrhage, and retinal pigment changes. Less commonly (2% to 5%), conjunctival hyperemia, conjunctivitis, corneal edema, decreased peripheral vision, hypotony, keratic precipitates, optic neuritis, photopsia, retinal vascular disease, visual field defect, vitreous hemorrhage, and vitreous opacity have been reported.[Ref]

More about fomivirsen ophthalmic

Patient resources

Other brands

Vitravene

Related treatment guides

References

1. "Product Information. Vitravene (fomivirsen ophthalmic)." Apothecon Inc (2022):

2. Perry CM, Balfour JAB "Fomivirsen." Drugs 57 (1999): 375-80

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.